Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACP 01

Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 04 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hemostemix
  • Developer Hemostemix; TheraVitae
  • Class Anti-inflammatories; Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic limb-threatening ischemia
  • Discontinued Angina pectoris; Cardiomyopathies; Heart failure; Thromboangiitis obliterans

Most Recent Events

  • 29 Aug 2023 Hemostemix plans to submit phase II clinical trial protocol with the regulatory body for Cardiomyopathies
  • 29 Aug 2023 Hemostemix plans a phase II trial for Cardiomyopathies (unspecified)
  • 07 Jul 2023 ACP 01 is still in phase II trials for Peripheral arterial disorders in USA and Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top